Virios Therapeutics is pleased that Maxim Group, LLC has initiated research coverage with its first research report authored by analyst Jason McCarthy. Note: Analyst research is conducted independently of the company, and Virios does not endorse or adopt the views expressed in any analyst research report.
Virios Therapeutics
Biotechnology
Alpharetta, Georgia 824 followers
Driven to improve patient outcomes by finally answering an underlying cause of fibromyalgia and related conditions.
About us
Virios Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). The company is led by an executive team highly experienced in the successful development of therapies for FM. Its lead candidate, IMC-1, was granted fast track designation by the FDA.
- Website
-
https://virios.com
External link for Virios Therapeutics
- Industry
- Biotechnology
- Company size
- 2-10 employees
- Headquarters
- Alpharetta, Georgia
- Type
- Public Company
Locations
-
Primary
44 Milton Avenue
Alpharetta, Georgia 30009, US
Employees at Virios Therapeutics
Updates
-
Brain Fog from Long Covid after 9 months shares gene signatures with acute infections. Future focus should be on antiviral medicine and not rehab or brain training. 50% LC still experiencing brain fog at 2 years. https://lnkd.in/eTQhYVUA
-
Many employers have a long Covid problem, making it more challenging to hire and retain employees and to support their productivity. In 2022, economics professors at Harvard University, estimated that long Covid costs the U.S. economy between $160 billion and $200 billion per year in lost wages and increased medical costs. In 2023, the Brookings Institution reported that 700,000 people were absent from the U.S. labor force due to the illness. The adults with Long Covid that are still working, may work fewer hours, or struggle with tasks that used to be easy for them, or both. In 2024, 6.9% of U.S. adults — 17.8 million people — have long Covid https://lnkd.in/gFvPpyVi
Long Covid at Work: A Manager’s Guide
hbr.org
-
https://lnkd.in/euqQqyxT Reinfection of COVID-19 Can Trigger Long Covid Reinfection, which is now the dominant type of SARS-CoV-2 infection, is not inconsequential; it can trigger de novo Long Covid or exacerbate its severity. Each reinfection contributes additional risk of Long Covid: Cumulatively, two infections yield a higher risk of Long Covid than one infection, and three infections yield a higher risk than two infections. Evidence from multiple studies with 2 to 3 years of follow-up indicates prolonged risk for many sequelae and that spontaneous recovery or return to baseline status is uncommon. Extended follow-up of the 1918 influenza pandemic, poliomyelitis outbreaks, and Epstein-Barr virus infections has demonstrated that new, disabling sequelae of these infections can occur multiple decades later.
Solving the puzzle of Long Covid
science.org
-
As reported in US News and World Report https://lnkd.in/g_AzysYd
Entering the Fifth Year of the Coronavirus, Where Does Long COVID Stand?
usnews.com
-
This clearly represents a large unmet medical need. https://lnkd.in/emzP4_2i
Millions of Americans suffer from long COVID. Why do treatments remain out of reach?
usatoday.com